 SAN DIEGO, Jan. 20, 2023 PRNewswire Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates AOCsTM, today announced that on January 20, 2023, the Compensation Committee of Aviditys Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its ...... 